Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine Zain

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOPJoo Y Song, Anamarija M Perry, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Blood Advances|June 5, 2024
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphomaJasmine Zain, Ni-Chun Tsai, Joycelynne Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.
The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.
Blood|November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A Olsen, Sean Whittaker, Rein Willemze, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOPJoo Y Song, Anamarija M Perry, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2019
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell LymphomaPhilippe Armand, Scott Rodig, Vladimir Melnichenko, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Blood Advances|June 5, 2024
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphomaJasmine Zain, Ni-Chun Tsai, Joycelynne Palmer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.
The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.
Blood|November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A Olsen, Sean Whittaker, Rein Willemze, et al.
Pageof 10